Registration Open for the 5th Annual Course on Proton Therapy Organized by IBA and Penn Medicine’s Department of Radiation Oncology

*Charting New Frontiers in Proton Therapy: The Penn Experience*

Louvain-La-Neuve, Belgium, Philadelphia, Pennsylvania USA, 18 July 2018 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, and the department of Radiation Oncology at Penn Medicine in partnership with OncoLink, proudly present the Fifth Annual Course on Proton Therapy. This will be held on November 16-18, 2018 at Penn Medicine in Philadelphia, Pennsylvania USA.

This unique educational opportunity presents medical professionals and administrators interested in proton therapy with a three-day proton therapy immersion program at Penn Medicine’s Roberts Proton Therapy Center, the largest and most integrated proton center in the world. The fifth presentation of this course will focus on the latest technology available in the field of proton therapy as well as shared expertise on how to build a strong and successful proton therapy center. The Penn Radiation Oncology team will share key insights from all areas of expertise including administration, clinical, physics, therapy, dosimetry, and more based on the successful operations of the Roberts Proton Therapy Center over the past eight years. Sessions are a mix of clinical and administrative topics and cover all aspects of running a thriving Center, including patient experience and patient engagement.

**James Metz, MD, Chair, Penn Radiation Oncology and Executive Director, OncoLink:** “We are excited to offer this course for the fifth year. As the interest in proton therapy grows both nationally and internationally, Penn’s Roberts Proton Therapy Center continues to be a leader in providing education and training to help develop the next wave of experts in the field. We have been pioneers, both in regards to the technology and in building staff expertise, and we are pleased to showcase our Center and share our experience with the world.”

**R. Scott Warwick, Executive Director, The National Association for Proton Therapy:** “The Penn Annual course is one of the most informative courses on proton therapy available for physicians, physicists and administrators. I would highly recommend it for anyone who is considering adding proton therapy to their cancer service line.”

**Eva Medel Báez, Assistant Professor Radiation Technologies and Medical Physics at the BUAP University in Mexico:** “I would encourage all future proton therapy users to attend this course, whether you are an administrator, medical physicist, radiation oncologist, radiation technologist, proton therapy researcher or dosimetrist. My fellow-attendee and I are now armed with multi-fold supporting arguments regarding
financing, benefits, administration, development and collaboration options to promote and work towards the acquisition of a proton therapy installation at our own institution.”

Target audiences for the course are: radiation oncology physicians, physicists, and administrators who are interested in learning about proton therapy. At the end of this educational activity, participants should be able to:

- Understand the logistics of establishing a proton therapy center with clinical and research capabilities
- Describe the current clinical indications and applications for proton therapy
- Comprehend the various technical considerations in proton therapy planning
- Explain the regulatory aspects of proton therapy planning and delivery from the standpoints of quality assurance and compliance
- Better perform their specific roles within the proton therapy center
- Build a dedicated patient community who are natural advocates for proton therapy

Details:

When: Friday, November 16 - Sunday, November 18, 2018
Where: Penn Medicine, Philadelphia, PA, USA
More information and registration: https://pennprotontherapycourse.iba-events.com/home

Contact us at ibapenncourse@iba-group.com with any questions related to organization and logistics and at RadOncProtonCourse@uphs.upenn.edu with any questions related to the content and agenda of the Course.
About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing around 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the Pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

About OncoLink

OncoLink was the first online cancer information site, started in 1994, and remains one of the largest. This award-winning site is maintained by a group of oncology healthcare professionals who understand the need of patients, caregivers and healthcare professionals. OncoLink’s content is continually updated and ranges from treatment and disease information for a newly diagnosed patient, support through the side effects of treatment, and into survivorship. OncoLink provides tools and educational materials to support the practice of busy practitioners.

The primary goal of OncoLink is to support patients, caregivers and practitioners through education. This education can empower patients to make informed treatment decisions, be active participants in their care and be their own advocate. More information can be found at: https://www.oncolink.org/

About the Roberts Proton Therapy Center

The Roberts Proton Therapy Center at Penn Medicine is the largest, most advanced facility of its kind in the world, and the only proton therapy center that is fully integrated with a National Cancer Institute (NCI) designated comprehensive cancer center.
For further information, please contact:

**IBA**

Thomas Ralet  
Vice-President Corporate Communication  
+32 10 475 890  
communication@iba-group.com

Jana Kulhankova  
Marketing Associate  
+32 10 203 652  
jana.kulhankova@iba-group.com

**Penn Medicine**

Fern Nibauer-Cohen  
Director, Patient Engagement and Business Development  
+1 (215) 662 3919  
Fern.Nibauer-Cohen@uphs.upenn.edu